Children's of Mississippi - Outpatient Specialty Clinic at Sanderson Tower (Level 1)
Return to Locations SearchAddress:
2500 N. State St.
Jackson, MS 39216
Contact Us:
(888) 815-2005
Parking:
Garage C
Parking Information and Maps
Directions:
Take I-55 to the Woodrow Wilson exit (98A) and turn RIGHT at the second intersection (directly after the VA Entrance). Next, take an immediate RIGHT on South University Drive then follow the signs directing you to the new Children's Parking Garage C.
Patients will enter the new Children's of Mississippi Hospital - Sanderson Tower entrance and will check in on the first floor using either the Kiosk or the centralized registration desks. Once registered, you and your child will receive stickers and a patient ID band that will allow access to the main elevators. Once you have boarded the main elevator, select Level 1 to reach the "White Tail Deer" clinic.
Our Care Specialties at this location:
Our Clinical Trials offered at this location:
Researchers at UMMC are committed to discovering innovative ways to prevent and treat the diseases that affect our daily lives. Clinical research studies play a vital role in the advancement of medicine and can improve the well-being of our families, friends, communities, and future generations. In this way, participation in clinical research studies furthers our vision to create "a healthier Mississippi."
Partnering with UMMC’s researchers may have many advantages, including:
- Gaining access to investigational treatments
- Increasing knowledge about your own health
- Giving the gift of improved health to our communities and future generations
- Contributing to the advancement of science by helping researchers learn more about how the human body and mind work or by helping find a cure or better treatments for diseases
Clinical Trials | Publish Date | Description | ||||||
---|---|---|---|---|---|---|---|---|
A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With Fragile X Syndrome - RECONNECTIRB Number: 2021-0614
Published: January 24, 2022
View Locations
Clinical Trial Locations:
|
20220124233647 |
<div><span style="color: #000000; font-family: &quot;Source Sans Pro&quot;, &quot;Helvetica Neue&quot;, Helvetica, Roboto, Arial, sans-serif; font-size: 14px; background-color: #ffffff;">The purpose of this study is to investigate of effective and safe ZYN002 transdermal gel is in patients with Fragile X Syndrom (FXS). </span><span style="font-family: Arial, sans-serif; font-size: 11pt;">The Drug Product
ZYN002 is a pharmaceutically manufactured </span><span style="font-family: Arial, sans-serif; font-size: 11pt;">Cannabidiol (CBD)</span><span style="font-family: Arial, sans-serif; font-size: 11pt;">. It is being developed as a clear
gel</span><i style="font-family: Arial, sans-serif; font-size: 11pt;"> </i><span style="font-family: Arial, sans-serif; font-size: 11pt;">that can be applied to the skin
(called transdermal delivery), to provide consistent, controlled levels of CBD
in the blood when it is given twice a day</span></div> zyn002;fragile x syndrome;cannabidiol (cbd);zynerba ZYN2-CL-033 Shelby Lee jingram Developmental Disorders Genetics Pediatrics |